205 related articles for article (PubMed ID: 10828626)
1. Elevated serum KL-6 levels in patients with systemic sclerosis: association with the severity of pulmonary fibrosis.
Sato S; Nagaoka T; Hasegawa M; Nishijima C; Takehara K
Dermatology; 2000; 200(3):196-201. PubMed ID: 10828626
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
[TBL] [Abstract][Full Text] [Related]
4. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal analysis of serum KL-6 levels in patients with systemic sclerosis: association with the activity of pulmonary fibrosis.
Yanaba K; Hasegawa M; Hamaguchi Y; Fujimoto M; Takehara K; Sato S
Clin Exp Rheumatol; 2003; 21(4):429-36. PubMed ID: 12942693
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum concentrations of polymorphonuclear neutrophilic leukocyte elastase in systemic sclerosis: association with pulmonary fibrosis.
Hara T; Ogawa F; Yanaba K; Iwata Y; Muroi E; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2009 Jan; 36(1):99-105. PubMed ID: 19208531
[TBL] [Abstract][Full Text] [Related]
7. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
Yanaba K; Hasegawa M; Takehara K; Sato S
J Rheumatol; 2004 Jun; 31(6):1112-20. PubMed ID: 15170923
[TBL] [Abstract][Full Text] [Related]
8. Elevated serum concentrations of triggering receptor expressed on myeloid cells-1 in diffuse cutaneous systemic sclerosis: association with severity of pulmonary fibrosis.
Tomita H; Ogawa F; Hara T; Yanaba K; Iwata Y; Muroi E; Yoshizaki A; Komura K; Takenaka M; Shimizu K; Hasegawa M; Fujimoto M; Sato S
J Rheumatol; 2010 Apr; 37(4):787-91. PubMed ID: 20156945
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive investigation of novel serum markers of pulmonary fibrosis associated with systemic sclerosis and dermato/polymyositis.
Kumánovics G; Minier T; Radics J; Pálinkás L; Berki T; Czirják L
Clin Exp Rheumatol; 2008; 26(3):414-20. PubMed ID: 18578962
[TBL] [Abstract][Full Text] [Related]
10. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
[TBL] [Abstract][Full Text] [Related]
11. Surfactant protein D and KL-6 serum levels in systemic sclerosis: correlation with lung and systemic involvement.
Bonella F; Volpe A; Caramaschi P; Nava C; Ferrari P; Schenk K; Ohshimo S; Costabel U; Ferrari M
Sarcoidosis Vasc Diffuse Lung Dis; 2011 Jul; 28(1):27-33. PubMed ID: 21796888
[TBL] [Abstract][Full Text] [Related]
12. Serum concentration of procollagen type I carboxyterminal propeptide in systemic sclerosis.
Kikuchi K; Ihn H; Sato S; Igarashi A; Soma Y; Ishibashi Y; Takehara K
Arch Dermatol Res; 1994; 286(2):77-80. PubMed ID: 8154928
[TBL] [Abstract][Full Text] [Related]
13. Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.
Sato S; Nagaoka T; Hasegawa M; Tamatani T; Nakanishi T; Takigawa M; Takehara K
J Rheumatol; 2000 Jan; 27(1):149-54. PubMed ID: 10648031
[TBL] [Abstract][Full Text] [Related]
14. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis.
Veselý R; Vargová V; Ravelli A; Massa M; Oleksák E; D'Alterio R; Martini A; De Benedetti F
J Rheumatol; 2004 Apr; 31(4):795-800. PubMed ID: 15088311
[TBL] [Abstract][Full Text] [Related]
15. Follow-up of serum KL-6 lung fibrosis biomarker levels in 173 patients with systemic sclerosis.
Kumánovics G; Görbe E; Minier T; Simon D; Berki T; Czirják L
Clin Exp Rheumatol; 2014; 32(6 Suppl 86):S-138-44. PubMed ID: 24773853
[TBL] [Abstract][Full Text] [Related]
16. Type III procollagen N-terminal propeptide, soluble interleukin-2 receptor, and von Willebrand factor in systemic sclerosis.
Lee YJ; Shin KC; Kang SW; Lee EB; Kim HA; Song YW
Clin Exp Rheumatol; 2001; 19(1):69-74. PubMed ID: 11247328
[TBL] [Abstract][Full Text] [Related]
17. Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and soluble gp130 in patients with systemic sclerosis.
Hasegawa M; Sato S; Fujimoto M; Ihn H; Kikuchi K; Takehara K
J Rheumatol; 1998 Feb; 25(2):308-13. PubMed ID: 9489824
[TBL] [Abstract][Full Text] [Related]
18. Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis.
Sato S; Fujimoto M; Hasegawa M; Komura K; Yanaba K; Hayakawa I; Matsushita T; Takehara K
Rheumatology (Oxford); 2004 Oct; 43(10):1261-6. PubMed ID: 15266059
[TBL] [Abstract][Full Text] [Related]
19. Serum KL-6 level as a monitoring marker in a patient with pulmonary alveolar proteinosis.
Nakajima M; Manabe T; Niki Y; Matsushima T
Thorax; 1998 Sep; 53(9):809-11. PubMed ID: 10319067
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of soluble CD31 in patients with systemic sclerosis (SSc): association with limited cutaneous SSc.
Sato S; Komura K; Hasegawa M; Fujimoto M; Takehara K
J Rheumatol; 2001 Nov; 28(11):2460-5. PubMed ID: 11708419
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
